CONMED Corp — Director's Dealing 2021

Mar 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CONMED CORP (CNMD)
CIK: 0000816956
Period of Report: 2021-03-01

Reporting Person: Berge Terence M (VP-Corporate Controller)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-01	Common Stock	M	3860	$39.87	Acquired	4864	Direct
2021-03-01	Common Stock	S	3860	$122.7727	Disposed	1004	Direct
2021-03-01	Common Stock	M	2800	$41.93	Acquired	3804	Direct
2021-03-01	Common Stock	S	2800	$122.5267	Disposed	1004	Direct
2021-03-01	Common Stock	M	2700	$59.96	Acquired	3704	Direct
2021-03-01	Common Stock	S	2700	$122.50	Disposed	1004	Direct
2021-03-01	Common Stock	M	5400	$78.76	Acquired	6404	Direct
2021-03-01	Common Stock	S	5400	$122.50	Disposed	1004	Direct
2021-03-01	Common Stock	M	2550	$97.69	Acquired	3554	Direct
2021-03-01	Common Stock	S	2550	$122.50	Disposed	1004	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-01	Options To Purchase Common Stock	$39.87	M	3860	Disposed	2026-03-01	Common Stock (3860)	Direct
2021-03-01	Options To Purchase Common Stock	$41.93	M	2800	Disposed	2031-03-01	Common Stock (2800)	Direct
2021-03-01	Options To Purchase Common Stock	$59.96	M	2700	Disposed	2028-03-01	Common Stock (2700)	Direct
2021-03-01	Options To Purchase Common Stock	$78.76	M	5400	Disposed	2029-03-01	Common Stock (5400)	Direct
2021-03-01	Options To Purchase Common Stock	$97.69	M	2550	Disposed	2030-03-02	Common Stock (2550)	Direct
2021-03-01	Options To Purchase Common Stock	$122.55	A	12000	Acquired	2031-03-01	Common Stock (12000)	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.66 to $122.99. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.50 to $122.62. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F3: The stock options were granted under the Company's 2015 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period.

F4: The stock options were granted under the Company's 2018 Long-Term Incentive Plan and generally vest in equal amounts over a five year period